Knight Cancer Institute
Knight Cancer Institute
News Article | May 25, 2017
The OHSU Knight Cancer Institute's project aims to develop strategies for improving treatment-resistant triple negative breast cancer, an aggressive form of breast cancer that lacks key receptors known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2). Using advanced microscopy, the team will leverage tools for quantitative analysis and visualization of images generated, together with computational approaches for integrating diverse molecular data types. Through analysis of core cell lines, patient-derived cultures and primary tumors, the team aims to uncover molecular networks that underlie disease progression and therapeutic response. Joe Gray, Ph.D., director of the OHSU Center for Spatial Systems Biomedicine (OCSSB) and the OHSU Knight Cancer Institute associate director for biophysical oncology will lead the investigative team as a principal investigator. "Triple negative breast cancer is a particularly difficult form of the disease to treat," said Gray. "Our goals in the CSBC Research Center are to identify the mechanisms by which these cancers evolve and adapt to become resistant to treatment, and to develop new strategies to counter these mechanisms. Our multidisciplinary approach treats these cancers as adaptive systems that can be controlled using multiple drug combinations." Co-principal investigators on the project include: Rosalie Sears, Ph.D., professor of molecular and medical genetics in the OHSU School of Medicine and a senior member of the Knight Cancer Institute; Claire Tomlin, Ph.D., the Charles A. Desoer Professor of Engineering in the Department of Electrical Engineering and Computer Sciences at the University of California, Berkeley; Adam Margolin, Ph.D., associate professor of biomedical engineering and director of computational biology in the OHSU School of Medicine and the Knight Cancer Institute. Overall research themes of the consortium's Research Centers address important questions in basic cancer research, including the emergence of drug resistance, the mechanisms underlying cancer metastasis, and the role of the immune system in cancer progression and treatment. The interdisciplinary investigators of the CSBC will integrate experimental biology with mathematical and computational modeling to gain insight into processes relevant to cancer initiation, progression and treatment options. The consortium brings together clinical and basic science cancer researchers with physician-scientists, engineers, mathematicians and computer scientists to tackle key questions in cancer biology from a novel point of view. "Cancer is a complex disease and it challenges our traditional approaches, making it hard to predict tumor growth and drug response," said Daniel Gallahan, Ph.D., deputy director of NCI's Division of Cancer Biology. "Cancer systems biologists embrace that complexity and use many different types of data to build mathematical models that allow us to make predictions about whether a tumor will metastasize or what drug combinations will be effective." In addition to applying systems biology approaches to gain important insight into cancer, each consortium Research Center supports an outreach program to promote training in interdisciplinary science, disseminate important research findings to the community, and to engage the public in cancer systems biology research. Sage Bionetworks in Seattle serves as the consortium's Coordinating Center, facilitating data and resource sharing and collaborative scientific activities across the nine Research Centers as well as two new Research Projects. More information can be found on the project website. The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit www.ohsu.edu/xd/health/services/cancer or follow us on Facebook and Twitter. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ohsu-knight-cancer-institute-selected-to-join-prestigious-national-consortium-receive-92-million-300464180.html
News Article | May 8, 2017
PORTLAND, Ore., SAN DIEGO, and TORONTO, May 08, 2017 (GLOBE NEWSWIRE) -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) announced the presentation of preclinical data demonstrating that CG’806, a highly potent pan-FLT3/BTK inhibitor, kills malignant cells in samples from patients with various hematologic malignancies. The data were presented in a poster on Sunday, May 7 at the 2017 American Association for Cancer Research (AACR) Conference Hematologic Malignancies: Translating Discoveries to Novel Therapies, held May 6-9 in Boston, MA. The poster, entitled CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity against AML Patient Samples with Mutant or Wild-Type FLT3, as well as Other Hematologic Malignancy Subtypes, demonstrated the broad potency of CG’806 against various hematologic malignancy cell lines and patient primary bone marrow specimens. In addition, data for CG’806 indicated greater potency of CG’806 when compared to other non-proprietary competitive agents in acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including the bromodomain inhibitors OTX-015 and JQ-1, and the FLT3 inhibitor quizartinib. “The analyses of CG’806 against primary hematologic malignancy patient samples and cultured cell lines show evidence of potent and broad drug activity in AML and other disease subtypes and support further development of this agent for hematologic malignancies,” said Stephen E. Kurtz, Ph.D., lead author and Research Assistant Professor at the OHSU Knight Cancer Institute. "These findings further strengthen our commitment to develop CG’806 as a targeted treatment for AML and other hematologic malignancies," commented William G. Rice, Ph.D., Chairman and Chief Executive Officer of Aptose. “We are actively preparing ’806 for clinical studies and look forward to filing an IND and taking the molecule into patients as soon as possible.” Through the Beat AML Initiative, primary patient mononuclear cells were derived from 82 patients diagnosed with AML. Primary samples were also collected from patients with myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN, n=15), acute lymphoblastic leukemia (ALL, n=17), and chronic lymphocytic leukemia (CLL, n=58). Sensitivity to CG’806 was evaluated across a range of concentrations after a 72-hour treatment. IC values were calculated as a measure of drug sensitivity and compared to other agents. Across the four general subtypes of hematologic malignancies in the dataset, there was broad sensitivity to CG’806, with 59% (48/82) of AML, 29% (5/17) of ALL, 53% (8/15) of MDS/MPN, and 40% (23/58) of CLL cases exhibiting an IC of less than 100 nM. Primary AML and CLL cells were sensitive to CG’806 with median IC values of 70 nM and 220 nM, respectively. Among the 38 tested AML samples with known FLT3 mutational status, the FLT3-ITD+ AML samples tended to have enhanced sensitivity to CG’806 (median IC = 20 nM, n=8) relative to the FLT3-WT samples (median IC = 120 nM, n=30). CG’806 also exerted potent anti-proliferative activity against human AML, B-ALL, mantle cell lymphoma, Burkitt’s lymphoma, and diffuse large B-cell lymphoma cell lines. In comparison to the FLT3 inhibitor quizartinib, CG’806 completely inhibited phosphorylation of FLT3 and STAT5 in MV4-11 cells, whereas quizartinib only partially inhibited their phosphorylation. The presentation will be published in the AACR Hematologic Malignancies Conference Proceedings. The poster can also be accessed here or at the Publications & Presentations section of the Aptose website, www.aptose.com. CG’806 is a once-daily, oral, first-in-class pan-FLT3/BTK inhibitor. This small molecule demonstrates potent inhibition of mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), eliminates AML tumors in the absence of toxicity in murine xenograft models, and represents a potential best-in-class therapeutic for patients with FLT3-driven AML. Likewise, CG’806 demonstrates potent, non-covalent inhibition of the Cys481Ser mutant of the BTK enzyme, as well as other oncogenic kinases operative in B cell malignancies, suggesting CG’806 may be developed for CLL and MCL patients that are resistant/refractory/intolerant to covalent BTK inhibitors. The Leukemia & Lymphoma Society and the Knight Cancer Institute at Oregon Health & Science University (OHSU) — joined by partnering medical institutions and industry collaborators — are performing groundbreaking research to better understand acute myeloid leukemia (AML). Led by researchers at the Knight Cancer Institute, Beat AML collects samples from participating AML patients treated at 11 academic medical centers across the U.S. Knight Cancer Institute researchers conduct deep genomic sequencing analyses on those samples to create a profile of the possible genetic drivers of AML. Researchers also test the sensitivity of patients' leukemic cells to a diverse panel of targeted therapies and novel combination regimens. The goal is to eventually match patients with treatments that precisely target their leukemia for durable remissions in AML. Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com. This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential of CG’806 and its clinical development as well as statements relating to Aptose’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
News Article | March 9, 2017
Ticked Off! Here's What You Need To Know About Lyme Disease Getting diagnosed of chronic myeloid leukemia, or CML, was tantamount to hearing a death sentence before the cancer drug imatinib mesylate, which is sold as Gleevec, was introduced in 2001. The drug was hailed as a wonder drug for patients with CML, a type of blood cancer that affects about 5,000 in the United States per year. Before the Food and Drug Administration approved the drug, less than one in three patients with CML survived five years after their diagnosis. Now, a new study gives credence to Gleevec being a wonder drug. Findings of the study, which were published in the New England Journal Medicine on Thursday, March 9, revealed that the drug can keep patients alive for 10 years or more. Investigators found that the cancer drug appears to keep the blood disease at bay 10 years into treatment and without signs of further safety risks. Study researcher Andreas Hochhaus, from Jena University Hospital in Germany, said that the findings provide additional evidence that the early "hype" around the drug was correct. Of the 500 patients involved in the study who were given Gleevec as their initial therapy, the researchers found that more than 83 percent were alive a decade later, a significant improvement when compared with the general survival rate of CML patients prior to the approval of Gleevec. The researchers said that life expectancy of the patients was almost normal and that they did not find evidence of new, long-range risk from Gleevec treatment, which is a welcome news since in the early days, there were concerns that use of the drug may boost risks for other health conditions such as heart disease. "Serious adverse events that were considered by the investigators to be related to imatinib were uncommon and most frequently occurred during the first year of treatment," the researchers wrote in their study. "Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects." Study researcher Brian Druker, of the Oregon Health and Science University Knight Cancer Institute, said that one of the advantages of treating CML patients with Gleevec is that most of those who were diagnosed are already in a chronic stage of the illness. Since CML patients can expect to live for decades, the researchers said it is crucial to monitor and manage age-related health issues and other conditions that coexist during the chronic phase of the disease. Gleever is the first targeted personalized medicine to be used and is considered the most successful. It ushered in the period of personalized cancer medicine that shows it is possible to shut down cells that enable cancer to grow without causing harm to the healthy ones. "Our results demonstrating Gleevec's high efficacy in CML tell us to realize the full promise of precision cancer medicine, we need to diagnose and treat patients earlier in the disease course," Druker said. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | October 27, 2016
SALT LAKE CITY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two new studies at the American Society of Dermatopathology (ASDP) annual meeting being held Oct. 27-30, 2016 in Chicago, Ill. The research being presented validates the accuracy of Myriad myPath® Melanoma in differentiating benign skin nevi from malignant melanoma. “We are presenting landmark data from the largest outcomes-based study ever performed with a melanoma diagnostic,” said Loren Clarke, M.D., medical director, Dermatology, Myriad Genetic Laboratories. “The myPath Melanoma test performed very well and identified patients with melanoma versus benign skin lesions with greater than 95 percent diagnostic accuracy, which is exceptional in molecular diagnostics for cancer, particularly given the extreme heterogeneity of melanoma.” “Pigmented or suspect skin lesions are difficult to diagnose in approximately 15 percent of cases,” said Sancy Leachman, M.D., Ph.D., chair of the Department of Dermatology in the Oregon Health & Science University School of Medicine and director of the Melanoma Research Program at the Knight Cancer Institute. “A highly accurate biomarker like the myPath Melanoma test should help dermatologists augment their diagnosis of melanoma, improve patient care and lower healthcare costs.” Below are the featured presentations at ASDP (#ASDP2016). Poster Presentation Title: Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcome. Presenter: Jennifer Ko. Date: Friday, Oct. 28, 2016: 4:15 – 5:00 p.m. and Saturday, Oct. 29, 2016 10:00 – 10:45 a.m. CT. In this study, research collaborators from the Cleveland Clinic, Stanford University and Nottingham University assessed the clinical accuracy (sensitivity and specificity) of the myPath Melanoma test against clinical outcomes in 182 patients with skin lesions (99 melanomas and 83 nevi) with more than 5 years of follow up. The results show that the myPath Melanoma test accurately differentiated benign lesions from melanoma with a sensitivity of 93.8 percent and a specificity of 96.2 percent when compared to known clinical outcomes. The diagnostic accuracy of the myPath Melanoma test was high even in a subset of difficult-to-diagnose cases and, in combination with two previous validation studies, the findings support its use as an adjunct method for the early and accurate diagnosis of melanoma. Podium Presentation Title: Gene Expression Signature as an Ancillary Method in the Diagnosis of Desmoplastic Melanoma. Presenter: Loren Clarke. Date: Sunday, Oct. 30, 2016: 8:20 – 8:30 a.m. CT. The objective of this study was to assess the accuracy of the myPath Melanoma test in the differentiation of desmoplastic melanoma (DM) from benign skin lesions. These lesions represent approximately one percent of melanomas, but are known to be very difficult to diagnose. The analysis included samples from 20 patients with DM and 27 from patients with benign moles (nevi). The results showed that the myPath Melanoma test was positive in 15 of the 20 known melanomas, negative in four and indeterminate in one. The myPath score was negative in 24 of the benign nevi and indeterminate in three. Based on these findings, the myPath Melanoma test demonstrated approximately 80 percent diagnostic accuracy in this very difficult-to-diagnose subtype. For more information about the meeting, please visit the ASDP website at https://www.asdp.org/annual-meeting/home/. Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company. About Melanoma Melanoma is one of the fastest growing cancers in the United States and can strike people of all ages, races and skin types. With a one-in-50 lifetime risk of developing melanoma, nearly 76,000 Americans are expected to be diagnosed with Stage I-IV melanoma and another 68,000 will be diagnosed with melanoma in situ – totaling approximately 144,000 total diagnoses. Early and accurate diagnosis of melanoma is critical for long-term survival. For more information visit: www.mypathmelanoma.com/ and www.myriadpro.com/melanoma. About Myriad myPath® Melanoma Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The test measures the expression of 23 genes and accurately distinguishes melanoma from benign nevi. About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting two new studies at the American Society of Dermatopathology Annual Meeting being held Oct. 27-30, 2016 in Chicago, Ill.; the accuracy and effectiveness of Myriad myPath Melanoma testing in differentiating benign skin nevi from malignant melanoma; and the Company’s strategic directives under the captions “About Myriad myPath Melanoma” and “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of a healthcare clinic in Germany and Sividon Diagnostic and our planned acquisition of Assurex Health; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
News Article | November 10, 2016
In Special Recognition of the work of The Stand Up To Cancer-Lustgarten Foundation Pancreatic Dream Team and in honor of Pancreatic Cancer Awareness Month SEATTLE, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a new myeloid gene expression collaboration to expand the company’s immuno-oncology portfolio. The Company, in conjunction with Lisa Coussens, Ph.D., Professor & Chair, Developmental & Cancer Biology Department, OHSU Knight Cancer Institute, Portland, Oregon, is developing two new myeloid focused research panels for the study of the innate immune response to cancer. An early version of the Myeloid Innate Immunity Panel will be made available to Dr. Coussens and her collaborators, as well as the Stand Up To Cancer – Lustgarten Foundation Pancreatic Dream Team members in an exclusive, advance offering during the month of November in conjunction with Pancreatic Cancer Awareness Month, after which the panels will be available to all researchers. “I am thrilled to be partnering with NanoString to create these novel myeloid-focused panels,” said Coussens. “We anticipate that through these efforts, we will enable a more complete understanding of the local interplay between myeloid immune components and neoplastic cells in tumors.” Myeloid cells play a key role in modulating activities fundamental to cancer development and are known to have both tumor promoting and anti-tumor functions. As myeloid cells are affected by and can have an impact on many types of cancer therapy, they are broadly applicable within immuno-oncology research. A heightened awareness of the importance of the mechanisms of immunotherapy resistance has brought the myeloid immune response into focus as a key modulator of the adaptive immune response. NanoString is currently working with Coussens on her efforts in understanding recruitment of myeloid cells into neoplastic tissue, and the subsequent regulation exerted by those myeloid cells on neoplastic cells and other cells within dynamic tumor microenvironments. The Myeloid Innate Immunity panel includes approximately 700 genes representing all major categories of myeloid cells, enabling quantitative evaluation of heterogeneous myeloid cell populations based on recruitment, differentiation, maturation status, and functional activities. The panels are optimized to work across a range of sample types including fresh frozen tissues, formalin-fixed paraffin-embedded (FFPE) samples, peripheral blood mononuclear cells and cell lysates. “It has been a pleasure to collaborate with Dr. Coussens and we are excited to share this work with the broader community of cancer researchers. The Myeloid panel is a collection of genes that encompass the many characteristics of the innate immune response that will help advance cancer research with obvious applications in infectious disease as well,” said Joseph Beecham, Ph.D., senior vice president of R&D at NanoString. “These myeloid panels are highly complementary to NanoString’s 770 gene PanCancer Immune Profiling Panel, layering a unique dimension of gene expression information that will provide insights into the modulation activities of the innate immune response.” Dr. Coussens is chair of the Department of Cell, Developmental & Cancer Biology at OHSU. Her research is focused on revealing the role that immune cells play in regulating solid tumor development. Coussens is a principal investigator on the Stand Up To Cancer – Lustgarten Foundation Pancreatic Cancer Convergence Dream Team in which her work is focused on clinical evaluation of immune-based therapies in pancreatic cancer. She has received numerous awards, including: the V Foundation Scholar Award, the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship, and the 2015 recipient of the 13th Rosalind E. Franklin Award from the National Cancer Institute. This is the latest in a series of research partnerships NanoString has with global leaders in immuno-oncology. NanoString and Coussens will be presenting independently at the upcoming Society for Immunotherapy of Cancer (SITC) conference taking place Wednesday, November 9 through Sunday, November 13 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Results from NanoString’s previously announced collaborations with Merck and MD Anderson Cancer Center will also be presented this week at AMP and SITC. - Title: Beyond PD-L1 IHC: A Gene Expression Based Test in development for anti-PD-1 response on the nCounter® Dx Analysis System - Speaker: Dr. Matthew Marton, Director of Genomics and Companion Diagnostics, Merck - Date/time: Wednesday, November 9th, 8 AM - 9 AM. - Title: The increasing clinical relevance of predictive biomarkers in cancer immunotherapy: can we afford to move forward without them? - Speakers: Alessandra Cesano, Alex Rueben (MDACC) & Jared Lunceford (Merck). - Date/time: Saturday, November 12th, 12:00 PM – 1:00 PM. About the OHSU Knight Cancer Institute: The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit www.ohsu.edu/xd/health/services/cancer or follow us on Facebook and Twitter. About the Stand Up To Cancer Initiative Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress. Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin was also a co-founder. Sung Poblete, Ph.D., R.N., has served as SU2C’s president since 2011. For more information on Stand Up To Cancer, visit www.standup2cancer.org. About NanoString Technologies, Inc. NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com. The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are registered trademarks of NanoString Technologies, Inc.
News Article | February 20, 2017
PORTLAND, OR - Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed as Gleevec. SWOG researchers are back with long-term findings from that study, which estimate that nearly one in four patients treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. "This is a really exciting finding," said Dr. Michael Heinrich, a SWOG investigator and a professor of medicine and cell and developmental biology at Oregon Health & Science University, where SWOG is based. "Until Gleevec arrived on the scene 15 years ago, patients with advanced GISTs faced a life expectancy of 18 months. Now we've learned that some might live a decade or longer. And we've come to understand which class of patients benefit the most from Gleevec." In new study results published in JAMA Oncology, researchers from SWOG, the international cancer research community supported by the National Cancer Institute, report a follow-up of patients originally enrolled in S0033, a SWOG-led trial supported by other groups in the NCI's National Clinical Trials Network (NCTN). This was a Phase III study that began in 2000. Initial results published in 2008 confirmed Gleevec as an effective treatment for advanced GIST patients, and recommended that therapy start with a 400 mg daily dose. The SWOG team decided to collect post-study data on S0033 patients, and from 2011 to 2015 gathered information. As part of their research, the team used next-generation DNA sequencing on some tumor tissue samples taken for S0033, which had been deposited in a biospecimen bank. The team reanalyzed tissue from 20 patients originally classified as having a wild-type tumor - one without any mutations of KIT, a gene implicated in 85 to 88 percent of all GISTs. Analysis showed that of the 695 eligible patients originally enrolled in S0033, 189 survived eight years or longer, with a 10-year estimate of overall survival of 23 percent, or nearly one in four patients. DNA sequencing also showed that survival rates were significantly higher for patients with a KIT exon-11 mutant GIST, when compared with patients whose tumor had a KIT exon-9 mutation or with no KIT mutations or mutations in the platelet-derived growth factor receptor gene, or PDGFRA. "Our findings show two things," Heinrich said. "One is that Gleevec has revolutionized treatment for patients with advanced GISTs. Our findings also highlight the importance of banked biospecimens to drive new scientific findings, and how tumor mutation testing can optimize treatment for cancer patients." GISTs are different from more common types of gastrointestinal tumors because of the type of tissue in which they start. GISTs belong to a group of cancers called soft-tissue sarcomas. Soft-tissue sarcomas develop in the tissues that support and connect the body, including muscles, nerves, tendons, and joints. GIST is a rare cancer, with about 6,000 new cases diagnosed in the United States each year. Researchers at Oregon Health & Science University have pioneered the treatment of GISTs. Dr. Brian Druker, director of the OHSU Knight Cancer Institute, conducted the most influential work in the development of Gleevec, and OHSU researchers have been part of major discoveries in the use of the drug to treat GISTs, as well as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Along with Heinrich, lead author of the JAMA Oncology article, the SWOG study team includes: Cathryn Rankin, MS, of Fred Hutchinson Cancer Research Center; Dr. Charles D. Blanke of Knight Cancer Institute; Dr. George Demetri of Dana-Farber Cancer Institute; Dr. Ernest Borden of Cleveland Clinic; Dr. Christopher Ryan of Knight Cancer Institute; Dr. Margaret von Mehren of Fox Chase Cancer Center; Dr. Martin Blackstein of Mount Sinai Hospital; Dr. Dennis Priebat of MedStar Hospital Research Center; Dr. William Tap of Memorial Sloan Kettering Cancer Center; Dr. Robert Maki of Norwell Health and Cold Spring Harbor Laboratory; Dr. Christopher Corless of Knight Cancer Institute; Dr. Jonathan Fletcher of Dana-Farber Cancer Institute; Kouros Owzar, PhD, of Duke University School of Medicine; John Crowley, PhD, of Cancer Research And Biostatistics; Dr. Robert Benjamin of University of Texas MD Anderson Cancer Center; and Laurence Baker, DO, of University of Michigan. Research reported in this article was supported by the NCI of the National Institutes of Health (NIH) in part under award numbers U10CA180888 and U10CA180819. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Novartis Pharmaceuticals also supported the research. SWOG is a global cancer research community of over 12,000 members in 47 states and six foreign countries who design and conduct publicly funded clinical trials. Since 1956, SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 2 million years of human life. The group is a proud member of the NCI's National Clinical Trials Network and the NCI Community Oncology Research Program, and is a major part of the cancer research infrastructure in the U.S. and the world. Headquartered at the Knight Cancer Institute at Oregon Health & Science University in Portland, Ore., SWOG's Statistics and Data Management Center is based at Fred Hutchinson Cancer Research Center in Seattle, Wash. and its Operations Office is located in San Antonio, Texas. Learn more at swog.org.
News Article | December 2, 2016
OHSU researcher Sudarshan Anand, Ph.D., has a contemporary analogy to describe microRNA: "I sometimes compare MicroRNA to tweets -- they're short, transient and constantly changing." Because microRNA is dynamic, it makes for a compelling target for cancer research. Anand, an assistant professor of radiation medicine in the School of Medicine and member of the Knight Cancer Institute, teamed up with a group of researchers to take a closer look at microRNA in the context of the tumor microenvironment. Their findings, published in Nature Communications, provide early evidence that a panel of microRNA may be used in the future as a biomarker for several types of cancer. Using a mouse model, Anand and colleagues demonstrated how microRNAs in the tumor microenvironment play a critical role in tumor progression and response to radiation therapy. With microRNAs, the team mimicked features of the autoimmune disease lupus within cancers to provoke an immune response. This promising, early research may one day translate to human cancer radiation and treatment, and begs the question: Can we use microRNA biomarkers to influence cancer radiation? Anand and team believe it is a line of inquiry worth pursuing. "Biology is such a random process," Anand says. "Two neighboring cells won't always act the same way, just like two people don't react the same way when they see the same event. We hope we will one day be able to read microRNAs and predict if a person's cancer is going to respond to radiation." More information about this paper can be found on the OHSU Knight Cancer Institute's science blog, Cancer Translated. This research was funded by: National Heart Lung Blood Institute (NHLBI)/NIH, grant R00HL112962, and the Barbara-Ann Miller Dive for the Cure Award from the OHSU Knight Cancer Institute. The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle - an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit http://www. or follow us on Facebook and Twitter.
News Article | December 8, 2016
Jennifer Lycette, M.D., understands the importance of treating patients with cancer at home in their in rural communities. It allows them to spend more time with their families and to focus on their treatment and recovery, not traveling. Lycette and other physicians who treat these patients are keenly aware of the numerous challenges they encounter. Consequently, they are strongly committed to ensuring rural patients have access to the latest targeted therapies and other cutting-edge treatment options. When faced with a breast cancer patient with underlying mental illness who was reluctant to try standard cancer treatments, Lycette asked herself an important question: "What good were targeted therapies when her coexisting mental illness prevented her from taking them?" Lycette outlines this and other concerns while sharing one patient's profound struggle in a New England Journal of Medicine "Perspective" paper published today titled, "Neglected -- Cancer Care and Mental Health in Rural America." An oncologist with the OHSU Knight Cancer Institute, Lycette treats patients in the coastal community of Astoria, Oregon. Astoria, like many other rural settings in the United States, has a severe shortage of psychiatric health care providers. According to the Department of Health and Human Services, approximately 4,000 Mental Health Professional Shortage Areas, defined as having less than one psychiatrist per 30,000 people, were identified in the United States in 2016. In reviewing what was available for the citizens of Clatsop County, of which the city of Astoria is a part, she found a disappointing zero psychiatrists per 100,000 people. Lycette's recounting of this patient's experience demonstrates the terrible impacts of insufficient or nonexistent psychiatric care. In her commentary, Lycette notes her inability to reach her patient with mental illness marked " ... the saddest final chapter in the devastating story of untreated mental illness, the true neglect." Lycette has served as the Columbia Memorial Hospital/OHSU Cancer Care Center's medical director for more than three years through the CMH/OHSU Knight Cancer Collaborative. In 2015, the collaborative, which has the goal to provide rural oncology care, announced the development of an 18,000 square-foot comprehensive cancer treatment center and specialty clinic in Astoria, scheduled to open in October 2017. The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle - an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit http://www. or follow us on Facebook and Twitter.
News Article | October 28, 2016
To celebrate Breast Cancer Awareness Month, all Dutch Bros Coffee locations will donate proceeds from the sale of its specialty “Be Aware” travel mugs to the advancement of breast cancer research at Oregon Health Sciences University Knight Cancer Institute (OHSU Knight Cancer Institute). Beginning on Saturday, Oct. 1, these specialty travel mugs will be available at all locations. Dutch Bros will donate $5 from the sale of every mug to raise awareness and funds for breast cancer research and the development of new techniques for detection, treatment and prevention. "The OHSU Knight Cancer Institute is doing an amazing job in breast cancer research," said Dutch Bros Co-Founder, Travis Boersma. "I cannot be more proud to partner with an organization that has such credibility and a tremendous track record for really making a difference. It's an honor to be a part such impactful work." Dutch Bros locations will donate funds raised throughout the month to the Oregon Health and Sciences University (OHSU) Knight Cancer Institute. Funds will directly benefit this institute as they continue their research. Donated funds support top researchers at OHSU as they discover new forms of breast cancer detection, treatment and prevention. “We are grateful for the support the OHSU Knight Cancer Institute has received from Dutch Bros and the Dutch Bros community over the years,” said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. “These valuable dollars will help our mission to build an early detection cancer research program, with the ultimate goal to end cancer as we know it.” To find a location near you, please visit http://www.dutchbros.com/locations About Dutch Bros Coffee Dutch Bros Coffee is the country’s largest privately held, drive-thru coffee company, with over 270 locations and over 7,000 employees in seven states. The rich, proprietary coffee blend is handcrafted from start to finish. Every ingredient is measured, every process timed, and every cup perfected. With a mission of, “Making a Difference, One Cup at a Time,” Dutch Bros donates over $2 million annually to nonprofit organizations and local causes selected by local owner-operators. Dutch Bros. Coffee is headquartered in Grants Pass, Ore., where it was founded in 1992 by Dane and Travis Boersma, brothers of Dutch descent. To learn more about Dutch Bros, visit http://www.dutchbros.com, like Dutch Bros Coffee on Facebook or follow @DutchBros on Twitter.